A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory

Vaccine

Volumn 30, Issue 41, 2012, Pages 5956-5966

  Loew Baselli, Alexandra ^a   Pavlova, Borislava G ^a   Fritsch, Sandor ^a   Poellabauer, Eva Maria ^a   Draxler, Wolfgang ^a   Kistner, Otfried ^a   Behre, Ulrich ^b   Angermayr, Rudolf ^c   Neugebauer, Johannes ^c   Kirsten, Karola ^d   Förster Waldl, Elisabeth ^e   Koellges, Ralph ^f   Ehrlich, Hartmut J ^a   Barrett, P Noel ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b Pediatric Practice   (Germany)

^c Pediatric Practice   (Austria)

^d Pediatric Practice   (Germany)

^e UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^f Pediatric Practice   (Germany)

Author keywords

Non adjuvanted; Pediatric; Vero cell derived; Whole virus H1N1 pandemic vaccine

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

2009 H1N1 INFLUENZA; ADOLESCENT; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; CRYING; DROWSINESS; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HEMAGGLUTINATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFANT; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; IRRITABILITY; MALAISE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEASONAL INFLUENZA; SHIVERING; SIDE EFFECT; SLEEP DISORDER; VOMITING;

ADOLESCENT; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; VACCINATION; VERO CELLS;

EID: 84865336354     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.039     Document Type: Article

References (64)

1. Chan M. World now at the start of 2009 influenza pandemic. June 11, 2011.2012 March 7.
2. Belshe R.B. Implications of the emergence of a novel H1 influenza virus. N Engl J Med 2009, 360:2667-2668.
3. Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58:467-470.
4. Abelin A., Colegate T., Gardner S., Hehme N., Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2011, 29:1135-1138.
5. World Health Organization Pandemic (H1N1) 2009 - update 101. 2012 March 8.
6. Kwan-Gett T.S., Baer A., Duchin J.S. Spring 2009 H1N1 influenza outbreak in King County, Washington. Disaster Med Public Health Prep 2009, 3(Suppl 2):S109-S116.
7. Mohamed A.G., Binsaeed A.A., Al-Habib H., Al-Saif H. Communicability of H1N1 and seasonal influenza among household contacts of cases in large families. Influenza Other Resp Viruses 2012, 6(3):e25-e29.
8. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361:1935-1944.
9. Novel Swine Origin Influenza A (H1N1) Virus Investigation Team, Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615.
10. Webb S.A., Pettila V., Seppelt I., Bellomo R., Bailey M., Cooper D.J., et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009, 361:1925-1934.
11. Arguedas A., Soley C., Lindert K. Responses to 2009 H1N1 vaccine in children 3-17 years of age. N Engl J Med 2010, 362:370-372.
12. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
13. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
14. Plennevaux E., Blatter M., Cornish M.J., Go K., Kirby D., Wali M., et al. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine 2011, 29:1569-1575.
15. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
16. Kistner O., Howard M.K., Spruth M., Wodal W., Brühl P., Gerencer M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007, 25:6028-6036.
17. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
18. Tambyah P.A., Wilder-Smith A., Pavlova B.G., Barrett P.N., Oh H.M., Hui D.S., et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012, 30:329-335.
19. Committee for Medicinal Products for Human Use (CHMP). Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision). European Medicines Agency, 2008. Report No.: EMEA/CPMP/VEG/4717/2003-Rev.1.
20. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines. European Agency for the Evaluation of Medicinal Products, 1997. Report No.: CPMP/BWP/214/96.
21. Nassim C., Christensen S., Henry D., Holmes S., Hohenboken M., Kanesa-Thasan N. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to one year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to <9 years of age. Pediatr Infect Dis J 2012.
22. Oh C.E., Lee J., Kang J.H., Hong Y.J., Kim Y.K., Cheong H.J., et al. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 2010, 28:5857-5863.
23. Arguedas A., Soley C., Abdelnour A., Sales V., Lindert K., Della C.G., et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccine 2011, 7:58-66.
24. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303:37-46.
25. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
26. Carmona A., Omenaca F., Tejedor J.C., Merino J.M., Vaman T., Dieussaert I., et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010, 28:5837-5844.
27. Garcia-Sicilia J., Gillard P., Carmona A., Tejedor J.C., Aristegui J., Merino J.M., et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011, 29:4353-4361.
28. Lu C.Y., Shao P.L., Chang L.Y., Huang Y.C., Chiu C.H., Hsieh Y.C., et al. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 2010, 28:5864-5870.
29. Scheifele D.W., Ward B.J., Dionne M., Vanderkooi O., Langley J.M., Dobson S., et al. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis J 2011, 30:402-407.
30. Palache A.M., Brands R., van Scharrenburg G.J. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997, 176(Suppl 1):S20-S23.
31. Vesikari T., Block S.L., Guerra F., Lattanzi M., Holmes S., Izu A., et al. Immunogenicity, safety, and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents 3-17 years of age. Pediatr Infect Dis J 2012.
32. Ohmit S.E., Petrie J.G., Cross R.T., Johnson E., Monto A.S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011, 204:1879-1885.
33. Barrett P.N., Berezuk G., Fritsch S., Aichinger G., Hart M.K., El-Amin W., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377:751-759.
34. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
35. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
36. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010, 10:18.
37. Black S., Nicolay U., Vesikari T., Knuf M., Del G.G., Della C.G., et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011, 30:1081-1085.
38. Petrie J.G., Ohmit S.E., Johnson E., Cross R.T., Monto A.S. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203:1309-1315.
39. H1N1 in post-pandemic period. World Health Organization, 2012. Available from: (accessed 14.03.12). http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/index.html.
40. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. World Health Organization, 2012. Available from: (accessed 14.03.12). http://www.who.int/entity/immunization/sage/3_Recommendation.pdf.
41. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2009/10. Robert Koch Institute, 2011. Available from: http://influenza.rki.de/Saisonberichte/2009.pdf.
42. Influenza in österreich, Saison 2009/2010. Austrian Agency for Food and Health Safety (AGES) Nationale Referenzzentrale für Influenza-Epidemiologie, 2011. Available from: http://www.ages.at/uploads/media/Microsoft_Word_-_Influenza_Jahresbericht_2009_20010pup_02.PDF.
43. von Kries R., Weiss S., Falkenhorst G., Wirth S., Kaiser P., Huppertz H.I., et al. Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany. PLoS One 2011, 6:e23955.
44. Gilca V., De S.G., Hamelin M.E., Boivin G., Ouakki M., Boulianne N., et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 2011, 30:35-41.
45. Walker W.T., de W.P., Andrews N., Oeser C., Casey M., Michaelis L., et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin Infect Dis 2012, 54:661-669.
46. Manzoli L., De V.C., Salanti G., D'Addario M., Villari P., Ioannidis J.P. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One 2011, 6:e24384.
47. Bernstein D.I., Zahradnik J.M., DeAngelis C.J., Cherry J.D. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6-36 months. Pediatrics 1982, 69:404-408.
48. Boyer K.M., Cherry J.D., Wright P.F., Lerman S.J., Gross P.A., Foy H.M., et al. Clinical reactions and serologic responses in healthy children aged six to 35 months after two-dose regimens of inactivated A/New Jersey/76 influenza virus vaccines. J Infect Dis 1977, 136(Suppl):S579-S583.
49. Gross P.A., Ennis F.A., Gaerlan P.F., Denson L.J., Denning C.R., Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977, 136:623-632.
50. Wright P.F., Thompson J., Vaughn W.K., Folland D.S., Sell S.H., Karzon D.T. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977, 136(Suppl):S731-S741.
51. Ehrlich H.J., Muller M., Kollaritsch H., Pinl F., Schmitt B., Zeitlinger M., et al. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine 2012, [epub ahead of print].
52. Ehrlich H.J., Muller M., Fritsch S., Zeitlinger M., Berezuk G., Low-Baselli A., et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009, 200:1113-1118.
53. Baxter R., Jeanfreau R., Block S.L., Blatter M., Pichichero M., Jain V.K., et al. A phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010, 29:924-930.
54. Nicholson K.G., Abrams K.R., Batham S., Clark T.W., Hoschler K., Lim W.S., et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
55. 2009-2010 Influenza Season Summary. Centers for Disease Control and Prevention, 2012. Available from: (accessed 14.03.12). http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/09-10summary.htm.
56. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
57. Diez-Domingo J., Garces-Sanchez M., Baldo J.M., Planelles M.V., Ubeda I., JuBert A., et al. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3-9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 2010, 29:e35-e46.
58. Nolan T., Richmond P.C., Formica N.T., Hoschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26:6383-6391.
59. Vajo Z., Kosa L., Szilvasy I., Pauliny Z., Bartha K., Visontay I., et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J 2008, 27:1052-1056.
60. Vesikari T., Karvonen A., Tilman S., Borkowski A., Montomoli E., Banzhoff A., et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010, 126:e762-e770.
61. Wu J., Liu S.Z., Dong S.S., Dong X.P., Zhang W.L., Lu M., et al. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Vaccine 2010, 28:6221-6227.
62. Parkman P.D., Hopps H.E., Rastogi S.C., Meyer H.M. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977, 136(Suppl):S722-S730.
63. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367:1657-1664.
64. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.